Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous ATR 1072 for the Treatment of PRKAG2 Syndrome

NCT07738107 is registered in ClinicalTrials.gov with Atrium Therapeutics as lead sponsor.

NCT NCT07738107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07738107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous ATR 1072 for the Treatment of PRKAG2 Syndrome
Lead sponsor
Atrium Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 14, 2026
Completion date
October 31, 2028
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac glycogenosis, cardiomyopathy, hypertrophic, wolff-parkinson-white syndrome